Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7% - Here's Why

Key Points

• Alto Neuroscience shares fell 4.7% to about $30.78 in mid-day trading, while trading volume was 84% below the average session volume.
• Analyst sentiment remains broadly positive: eight analysts rate the stock a Buy, one Hold and two Sell, producing a “Moderate Buy” consensus and an average price target of $36.62.
• The company reported a quarterly loss of $0.65 per share, beating estimates of a $0.73 loss. Several institutional investors also recently increased their positions or initiated new stakes in Alto Neuroscience.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) shares dropped 4.7% during mid-day trading on Friday . The company traded as low as $30.51 and last traded at $30.7820. Approximately 57,990 shares were traded during mid-day trading, a decline of 84% from the average session volume of 367,339 shares. The stock had previously closed at $32.30.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ANRO. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. BTIG Research raised their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a "buy" rating in a research note on Thursday. Wolfe Research began coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They set an "outperform" rating on the stock. Chardan Capital reiterated a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Finally, Wedbush increased their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Alto Neuroscience has an average rating of "Moderate Buy" and a consensus target price of $36.62.

Alto Neuroscience Stock Down 4.8%

The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The stock has a market capitalization of $1.08 billion, a P/E ratio of -12.68 and a beta of 1.06. The firm has a 50 day moving average of $25.70 and a 200-day moving average of $22.68.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.08. On average, equities research analysts expect that Alto Neuroscience, Inc. will post -3.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ANRO. Commodore Capital LP acquired a new stake in Alto Neuroscience during the fourth quarter worth $32,453,000. Perceptive Advisors LLC raised its stake in shares of Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company's stock valued at $31,762,000 after buying an additional 1,629,027 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the period. Spruce Street Capital LP lifted its holdings in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company's stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC acquired a new stake in shares of Alto Neuroscience during the 4th quarter valued at about $18,433,000.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source